AT THE EULAR 2017 CONGRESS

MADRID (FRONTLINE MEDICAL NEWS) – Additional real-world evidence confirmed that biological disease modifying drugs used to treat rheumatoid arthritis produced no spikes in new cancers or in cancer recurrences in registry data from tens of thousands of Swedish patients.

Among rheumatoid arthritis patients with a history of cancer, patients treated with a tumor necrosis factor inhibitor (TNFi) were not at an increased risk for cancer recurrence, Johan Askling, MD , said at the European Congress of Rheumatology. In a second study, patients with rheumatoid arthritis (RA) treated with a non-TNFi, biological, disease-modifying drug, specifically abatacept, rituximab, or tocilizumab, had no significantly different rate of new cancer onset when compared with RA patients who never received a biological disease modifying drug nor when compared with the general Swedish adult population, said Dr. Askling, a professor of clinical epidemiology at the Karolinska Institute in Stockholm.

He qualified the findings on cancer recurrence as limited to patients with a history of relatively common cancers – colorectal, lung, breast, or prostate – as well as to patients who were several years removed from their cancer diagnosis and were in stable remission, the types of cancer patients with RA who have received a TNFi in real-world Swedish practice. Similarly, the findings on new onset cancers were limited to patients developing one of several different types of relatively common cancers. In both studies, follow-up was relatively brief, an average of about 5 years. Much longer follow-up is needed for deeper reassurance about the long-term cancer safety of biological disease modifying drugs.

“Five-year data are a good start, but we need data on 30-year risk,” Dr. Askling said in an interview.

The cancer-recurrence risk study with TNFi treatment used data collected by the Swedish national outpatient care registry on nearly 62,000 people, the Swedish cancer registry, and a rheumatology treatment registry called ARTIS . It also included patients treated during 2001-2014. From these sources, the researchers identified 446 RA patients with a history of at least one cancer who then began treatment with any type of TNFi and matched these cases with 1,278 similar RA patients with a cancer history who had never received a biologic drug. On average, the patients were nearly 10 years removed from their initial cancer diagnoses, and the average duration on TNFi treatment was nearly 5 years.

The adjusted hazard ratio for cancer recurrence among the TNFi recipients was reduced by a nominal 30%, compared with that of the controls, a difference that was not statistically significant, Dr. Askling reported .

The second study used data from similar sources for patients treated during 2006-2014 and included nearly 100,000 Swedes from the general population, more than 42,000 RA patients who did not receive a biological drug, more than 14,000 treated with either a first or second TNFi drug, and 1,693 patients treated with tocilizumab (Actemra), 1,894 on abatacept (Orencia), and 3,119 on rituximab (Rituxan).

The rates of new onset cancer in any of these treatment groups, including the patients on tocilizumab, abatacept, or rituximab, was not significantly different from the rate among RA patients who never received a biologic drug, nor from the general Swedish population rate, Dr. Askling said .

This is “one of the first large-scale assessments” of the cancer risk posed by non-TNFi biological drugs, aside from what was reported from the pivotal trials for these drugs, Dr. Askling said.

Dr. Askling has received research support from AbbVie, Lilly, MSD, Pfizer, Roche, and UCB.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Ads

You May Also Like

How to reduce readmissions after vascular procedures

AT THE NORTHWESTERN VASCULAR SYMPOSIUM CHICAGO (FRONTLINE MEDICAL NEWS) – As Medicare ratchets up ...

Occult micrometastases in N2 lymph nodes correlated with shorter survival in NSCLC

In patients with non–small cell lung cancer (NSCLC) designated stage I by conventional histopathology, ...

Nasal infantile hemangiomas develop most complications

FROM PEDIATRIC DERMATOLOGY Infantile hemangiomas of the nose develop more complications than those at ...